The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Current and emerging therapeutic strategies in beta-thalassemia
Ali Taher, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, discusses the current standard of care (SOC) in beta-thalassemia, highlighting novel therapeutic strategies for this disease. Prof. Taher explains that whilst curative strategies such as bone marrow transplantation (BMT), and emerging strategies targeting erythropoiesis and the alpha:beta imbalance observed in beta-thalassemia, are being developed, transfusion and iron chelation therapy will remain the SOC in third-world countries. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Novartis Pharmaceuticals: Consultancy, Research funding; Bristol-Myers Squibb (Celgene): Consultancy, Research funding; Ionis Pharmaceuticals: Consultancy, Research Funding; Vifor: Consultancy, Research Funding; Imara: Consultancy, Research Funding; Agios: Consultancy
